Presentation is loading. Please wait.

Presentation is loading. Please wait.

Early decreases in blood eosinophil levels with reslizumab

Published byYildiz Kaba Modified over 5 years ago

Similar presentations

Presentation on theme: "Early decreases in blood eosinophil levels with reslizumab"— Presentation transcript:

1 Early decreases in blood eosinophil levels with reslizumab
Pascal Chanez, MD, Mirna McDonald, MS, Margaret Garin, MD, Kevin Murphy, MD  Journal of Allergy and Clinical Immunology  Volume 143, Issue 4, Pages (April 2019) DOI: /j.jaci Copyright © Terms and Conditions

2 Fig 1 Mean eosinophil counts over 52 weeks of treatment with reslizumab or placebo in patients with early eosinophil data (study 1 only) and all patients in studies 1 and 2. EOS, Eosinophil count data. P values shown for treatment difference (reslizumab vs placebo) at specified time point. All P values derived from Student t test. Treatment differences at baseline were not significant in study 1 or studies 1 and 2. *P < .001. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © Terms and Conditions

Download ppt "Early decreases in blood eosinophil levels with reslizumab"

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria  Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria  Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
Alalia Berry, MD, William W. Busse, MD 

Alalia Berry, MD, William W. Busse, MD 
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
The Editors' Choice Journal of Allergy and Clinical Immunology

The Editors' Choice Journal of Allergy and Clinical Immunology
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Practice Notes from the AAAI

Practice Notes from the AAAI
Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.
The Editors' Choice Journal of Allergy and Clinical Immunology

The Editors' Choice Journal of Allergy and Clinical Immunology
A randomized multicenter study evaluating Xolair persistence of response after long- term therapy  Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy  Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,
Kevin Murphy, MD, Joshua Jacobs, MD, Leif Bjermer, MD, John M

Kevin Murphy, MD, Joshua Jacobs, MD, Leif Bjermer, MD, John M
Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison  William Busse, MD, Geoffrey Chupp,

Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison  William Busse, MD, Geoffrey Chupp,

Similar presentations

Ads by Google